AzTrials
AzTrials

Hypotension Drug-InducedPhase 4NCT05368376

Is Labetalol More Effective Than Metoprolol for Controlled Hypotensive Anesthesia During Endoscopic Nasal Surgeries?

A Phase 4 study testing Labetalol Hydrochloride Oral Tablet and Metoprolol Tartrate Oral Tablet in people with Hypotension Drug-Induced, run by Damanhour Teaching Hospital at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Mucosal bleeding is the most frequent complication with endoscopic nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, leading to increased complications, operation duration, and blood loss. Read more about this study

Who is it for?
Ages 21 to 50 years
Conditions the study is for
Hypotension Drug-Induced
What is being tested?
Labetalol Hydrochloride Oral Tablet and Metoprolol Tartrate Oral Tablet
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteEgypt
Study dates
1 Apr 2021to 15 Oct 2022
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 50 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • American Society of Anesthesiologists (ASA) physical status ≤ II
  • Age from 21 to 50 years
  • Body Mass Index (BMI) ≤ 35 kg/m2

Who cannot join

  • ASA physical status > II
  • Age < 21 years or > 50 years
  • Pregnant women
  • Breastfeeding
  • Bronchial asthma
  • Chronic obstructive pulmonary disease
Show all 24Show fewer
  • Hypertension
  • Ischemic heart disease
  • Rheumatic heart disease
  • Heart failure
  • Heart block
  • Sick sinus syndrome
  • Sinus bradycardia
  • Chronic hypotension
  • Anemia (Hb < 10 g/dl)
  • Renal or hepatic dysfunction
  • Central nervous system disease
  • Bleeding diathesis
  • Diabetes Mellitus
  • Allergic fungal sinusitis
  • Patients on beta-blockers, tricyclic antidepressants, alcohol or drug abuse, anticoagulation therapy, agents influencing the autonomic nervous system
  • Patients using pacemakers
  • Allergy to the study drugs
  • Any contraindication of oral intake

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Damanhour Teaching Hospital

    Damanhūr, El-Beheira

Other trials in Egypt

About this study

Official title: Is Labetalol More Effective Than Metoprolol for Controlled Hypotensive Anesthesia During Endoscopic Nasal Surgeries? A Randomized Clinical Trial.

Background: Mucosal bleeding is the most frequent complication with endoscopic nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, leading to increased complications, operation duration, and blood loss. There are several pharmacological techniques for the appropriate control of intraoperative bleeding.

Objectives: To compare the safety and efficacy of oral labetalol versus oral metoprolol as a premedication for controlled hypotensive anesthesia during endoscopic nasal surgeries.

Patients and Methods: This is a randomized, double-blind, phase four, comparative clinical trial; carried out on 60 patients, who were candidates for endoscopic nasal surgeries under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group L, received oral labetalol, and group M, received oral metoprolol.

Being tested
Labetalol Hydrochloride Oral Tablet, Metoprolol Tartrate Oral Tablet
Keywords
controlled hypotension, endoscopic nasal surgery, labetalol, metoprolol
Medical subject headings
Hypotension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Labetalol Hydrochloride Oral TabletDrug

    Also called Labipress tablets

    Labetalol 200 mg

  • Metoprolol Tartrate Oral TabletDrug

    Also called Betaloc tablets

    Metoprolol 100 mg

Study groups in NCT05368376
Study groupRoleWhat they receive
Group L (n=30)Active comparatorLabetalol group
Receives: Drug: Labetalol Hydrochloride Oral Tablet
Group M (n=30)Active comparatorMetoprolol group
Receives: Drug: Metoprolol Tartrate Oral Tablet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean and Standard deviation of Blood loss (ml)(mean±SD)

    Amount of blood loss at the end of surgery

    Measured: 30 minutes after the end of surgery

Secondary outcomes (4)
  1. Mean and Standard deviation of Sevoflurane concentration (%)(mean±SD)

    Concentration of sevoflurane used during surgery

    Measured: 30 minutes after the end of surgery

  2. Mean and Standard deviation of Heart rate (beat/min.)(mean±SD)

    Before premedication (T_B), 2 hours after premedication (T0), 1 minute after induction of anesthesia (T1), at 15 (T15), 30 (T30), 45 (T45), 60 (T60), 75 (T75) minutes after induction of anesthesia, at post anesthesia care unit (T_PACU)

    Measured: 30 minutes after the end of surgery

  3. Mean and Standard deviation of Mean Blood Pressure (mmHg)(mean±SD)

    Before premedication (T_B), 2 hours after premedication (T0), 1 minute after induction of anesthesia (T1), at 15 (T15), 30 (T30), 45 (T45), 60 (T60), 75 (T75) minutes after induction of anesthesia, at post anesthesia care unit (T_PACU)

    Measured: 30 minutes after the end of surgery

  4. Number of participants and Percentage of Drug-related side effects

    Number of participants and Rate of: Bradycardia, Hypotension, Dysrhythmia, Bronchospasm, and Postoperative nausea and vomiting (PONV)

    Measured: 30 minutes after the end of surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 May 2022
  2. Study start1 Apr 2021
  3. Primary completion1 Oct 2022
  4. Study completion15 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05368376
Sponsor's protocol ID
DTH: 22001
Status last verified
Sep 2021
First submitted
5 May 2022
Last updated
28 Sep 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Labetalol Hydrochloride Oral Tablet and Metoprolol Tartrate Oral Tablet in people with Hypotension Drug-Induced, run by Damanhour Teaching Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean and Standard deviation of Blood loss (ml)(mean±SD) (time frame: 30 minutes after the end of surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in